Merck & Co. (MRK) : Lynch Associatesin scooped up 12,604 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 77,018 shares of Merck & Co. which is valued at $4,530,199.Merck & Co. makes up approximately 1.98% of Lynch Associatesin’s portfolio.
Other Hedge Funds, Including , Meritage Portfolio Management reduced its stake in MRK by selling 3,760 shares or 4.29% in the most recent quarter. The Hedge Fund company now holds 83,854 shares of MRK which is valued at $4,932,292. Merck & Co. makes up approx 0.54% of Meritage Portfolio Management’s portfolio.Regentatlantic Capital reduced its stake in MRK by selling 7,785 shares or 6.11% in the most recent quarter. The Hedge Fund company now holds 119,567 shares of MRK which is valued at $7,029,344. Merck & Co. makes up approx 0.66% of Regentatlantic Capital’s portfolio.Highland Capital Management reduced its stake in MRK by selling 3,289 shares or 0.55% in the most recent quarter. The Hedge Fund company now holds 594,938 shares of MRK which is valued at $34,976,405. Merck & Co. makes up approx 2.92% of Highland Capital Management’s portfolio.Gw&k Investment Management boosted its stake in MRK in the latest quarter, The investment management firm added 20,859 additional shares and now holds a total of 346,414 shares of Merck & Co. which is valued at $20,628,954. Merck & Co. makes up approx 0.42% of Gw&k Investment Management’s portfolio. Carlson Capital Management added MRK to its portfolio by purchasing 3,763 company shares during the most recent quarter which is valued at $223,334. Merck & Co. makes up approx 0.08% of Carlson Capital Management’s portfolio.
Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.